Trevor Baglin
Private Equity Investor bij Medicxi Ventures (Jersey) Ltd.
Actieve functies van Trevor Baglin
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
Medicxi Ventures (Jersey) Ltd.
 Medicxi Ventures (Jersey) Ltd. Investment ManagersFinance Medicxi Ventures (Jersey) Ltd. (Medicxi) is an independent venture capital firm founded in 2016 by Francesco de Rubertis, Michèle Ollier, and Kevin S. Johnson. The firm is headquartered in London. | Private Equity Investor | 01-01-2017 | - |
Loopbaan van Trevor Baglin
Eerdere bekende functies van Trevor Baglin
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
Z Factor Ltd.
 Z Factor Ltd. BiotechnologyHealth Technology Z Factor Ltd. operates as a drug discovery company. It identifies and develops therapeutic agents to treat alpha-1-antitrypsin deficiency. The company was founded by James Huntington in 2015 and is headquartered in Babraham, the united Kingdom. | Corporate Officer/Principal | - | - |
SuperX Ltd.
 SuperX Ltd. BiotechnologyHealth Technology SuperX Ltd. operates as a biopharmaceutical firm. It develops antibodies with anticoagulant properties. The company was founded by Trevor Baglin, David Grainger, and Jim Huntington and is headquartered in Cambridge, the United Kingdom. | Directeur/Bestuurslid | 10-11-2015 | - |
| Hoofd Techniek/Wetenschap/O&O | 10-11-2015 | - | |
| Oprichter | 10-11-2015 | - | |
XO1 Ltd.
 XO1 Ltd. Medical/Nursing ServicesHealth Services XO1 Ltd. develops a novel anticoagulant drug. The firm operates as a biopharmaceutical company. The company was founded by David J. Grainger on February 28, 2013 and is headquartered in High Wycombe, the United Kingdom. | Oprichter | - | - |
ApcinteX Ltd.
 ApcinteX Ltd. BiotechnologyHealth Technology ApcinteX Ltd. develops and markets anticoagulant APC pathway to treat haemophilia. The company is headquartered in London, the United Kingdom. | Oprichter | 16-06-2014 | - |
Opleiding van Trevor Baglin
| The University of Manchester | Undergraduate Degree |
| University of Cambridge | Graduate Degree |
| University of Birmingham | Doctorate Degree |
Statistieken
Internationaal
| Verenigd Koninkrijk | 9 |
Operationeel
| Founder | 3 |
| Director/Board Member | 1 |
| Chief Tech/Sci/R&D Officer | 1 |
Sectoraal
| Consumer Services | 4 |
| Health Technology | 4 |
| Health Services | 2 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
| Bedrijven in privébezit | 5 |
|---|---|
XO1 Ltd.
XO1 Ltd. Medical/Nursing ServicesHealth Services XO1 Ltd. develops a novel anticoagulant drug. The firm operates as a biopharmaceutical company. The company was founded by David J. Grainger on February 28, 2013 and is headquartered in High Wycombe, the United Kingdom. | Health Services |
Medicxi Ventures (Jersey) Ltd.
Medicxi Ventures (Jersey) Ltd. Investment ManagersFinance Medicxi Ventures (Jersey) Ltd. (Medicxi) is an independent venture capital firm founded in 2016 by Francesco de Rubertis, Michèle Ollier, and Kevin S. Johnson. The firm is headquartered in London. | Finance |
Z Factor Ltd.
Z Factor Ltd. BiotechnologyHealth Technology Z Factor Ltd. operates as a drug discovery company. It identifies and develops therapeutic agents to treat alpha-1-antitrypsin deficiency. The company was founded by James Huntington in 2015 and is headquartered in Babraham, the united Kingdom. | Health Technology |
ApcinteX Ltd.
ApcinteX Ltd. BiotechnologyHealth Technology ApcinteX Ltd. develops and markets anticoagulant APC pathway to treat haemophilia. The company is headquartered in London, the United Kingdom. | Health Technology |
SuperX Ltd.
SuperX Ltd. BiotechnologyHealth Technology SuperX Ltd. operates as a biopharmaceutical firm. It develops antibodies with anticoagulant properties. The company was founded by Trevor Baglin, David Grainger, and Jim Huntington and is headquartered in Cambridge, the United Kingdom. | Health Technology |
- Beurs
- Insiders
- Trevor Baglin
- Ervaring
